stockrowImmunovant, Inc.
IMVT Healthcare Biotechnology
- EPS
- −5.63%
- Free cash flow
- −5.96%
Quarter to June 2026, against a year earlier
Follow IMVT
Alert me
Immunovant, Inc. (IMVT) Free cash flow margin
Immunovant, Inc.'s free cash flow margin over the twelve months to 30 June 2026 was 0.00%, down 0.0 percentage points from fiscal 2026 (0.00%). Over the past ten years it has ranged from 0.00% (fiscal 2026) to 0.00% (fiscal 2026) — the current reading is the highest in ten years. That is in line with the Biotechnology industry median of 0.00% and in line with the Healthcare sector median of 0.00%.
Free cash flow margin, annual
Embed this chart
Annual newest first
| Period | Free cash flow margin | Change (points) |
|---|---|---|
| FY2026 | 0.00% | 0.00 |
| FY2025 | 0.00% | 0.00 |
| FY2024 | 0.00% | 0.00 |
| FY2023 | 0.00% | 0.00 |
| FY2022 | 0.00% | 0.00 |
| FY2021 | 0.00% | 0.00 |
| FY2020 | 0.00% | 0.00 |
| FY2019 | 0.00% | — |
Against its own ten years
Free cash flow margin against peers
| Company | Free cash flow margin |
|---|---|
| LGND Ligand Pharmaceuticals Incorporated compare | 31.4% |
| KOD Kodiak Sciences Inc. compare | 0.00% |
| IMVT Immunovant, Inc. | 0.00% |
| MANE Veradermics Incorporated compare | 0.00% |
| BLTE Belite Bio, Inc. Sponsored ADR compare | 0.00% |
| PTCT PTC Therapeutics, Inc. compare | −22.4% |
| MIRM Mirum Pharmaceuticals, Inc. compare | −46.0% |
| IONS Ionis Pharmaceuticals, Inc. compare | −64.9% |
| CGON CG Oncology, Inc. compare | −2,879.6% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Free cash flow margin is
Free Cash Flow Margin tells an investor how much of each sale turns into cash the company keeps after paying for investment in its assets.
(Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)) ÷ Revenue